Followers | 36 |
Posts | 2,689 |
Boards Moderated | 0 |
Alias Born | 06/09/2011 |
Twitter Profile: | Temporarily Unavailable |
Follow on Twitter: | Follow @ Temporarily Unavailable |
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
BRIEF-Brazil PetroRio says looking to buy producing offshore asset from Petrobras
REUTERS 11:23 AM ET 3/24/2016
March 24 (Reuters) -
* The asset Brazil oil firm PetroRio is looking to buy from state-run oil company Petrobras is offshore and in production, PetroRio's CFO told Reuters Further company coverage: and (Reporting by Marta Nogueira)
BRIEF-Brazil's Petrorio says in advanced talks to buy a Petrobras asset
REUTERS 10:54 AM ET 3/24/2016
March 24 (Reuters) -
* Brazilian oil firm Petrorio is in advanced talks with Petrobras to buy an asset from the state-run oil company, Petrorio's chief finance officer said on a conference call on Thursday
* The CFO gave no further details on the asset Petrorio is looking to buy
* Petrobras is in the process of selling assets as it looks to reduce its debt burden in the face of falling oil prices and a broad corruption probe focused on the company Further company coverage: and (Reporting By Marta Nogueira)
Thanks Drilla, I respect your opinion a lot and appreciate your posts here on HRTPY.
Drilla- where do you see the PPS going with this buyback and through remainder of 2016? TIA!
I believe you are speculating Neil Woodford was the author of that letter in referenced in the 10K below. I do not agree with you.
Enjoyed reading this article, hopefully this can get done, thanks TC!
You are correct cannon as the following are the after hours trades from Nasdaq.
After Hours Time (ET) After Hours Price After Hours Share Volume
17:34 $ 1.34 Low 443
16:34 $ 1.40 High 645
16:00 $ 1.40 59
16:00 $ 1.40 4,452
Read more: http://www.nasdaq.com/symbol/nwbo/after-hours#ixzz43LFzQjUo
You can add me to the class action too!
Yes this very helpful! Thank you Evaluate!
Here is the link to that trial at UCLA with Dr. Liau, Dr. Prins, etc.I would have to assume NWBO is producing the DC vaccine for this study but not a 100% sure. I guess we could ask Les Goldman about this unless Flipper already knows.
https://www.clinicaltrials.gov/ct2/show/NCT01204684?term=NCT+01204684&rank=1
Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase II Clinical Trial Evaluating Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen +/- Toll-like Receptor Agonists for the Treatment of Malignant Glioma
I agree with you. I am encouraged by NW and his team's reply to questions on his blog.
It definitely speaks of positive outlook based on the responses. It is of my opinion, that he is is still under an NDA due to screening hold and when lifted may jump back into NWBO.
I do not believe his relationship is fractured in any way with NWBO as well. We are all welcome to our opinion and I will eat crow if I am wrong, but I do not think I am. GLTA!
Buck, do you think Ponezumab with ILNS is the route Pfizer is going with here as we can see from the trial information below? No mention of Ponezumab in that post.
Study Evaluating the Safety,Tolerability and Efficacy of PF-04360365 in Adults With Probable Cerebral Amyloid Angiopathy
This study has been completed.
Sponsor:
Pfizer
Information provided by (Responsible Party):
Pfizer
ClinicalTrials.gov Identifier:
NCT01821118
First received: March 4, 2013
Last updated: March 7, 2016
Last verified: March 2016
History of Changes
https://clinicaltrials.gov/ct2/show/NCT01821118?term=Ponezumab&rank=5
Interesting point that if or when Woodford does buy again in NWBO with the float at 58M, Woodford can purchase on the open market and immediately drive up the PPS very quickly.
Northwest Biotherapeutics Incorporated $ 1.36
NWBO (NASDAQ) -0.08
Short Interest (Shares Short) 12,023,400
Days To Cover (Short Interest Ratio) 36.6
Short Percent of Float 19.96 %
Short Interest - Prior 11,934,200
Short % Increase / Decrease 0.75%
Short Squeeze Ranking™ -3
% From 52-Wk High ($12.55) -89.16 %
% From 52-Wk Low ($1.32) 3.03 %
% From 200-Day MA ($4.24) -67.92 %
% From 50-Day MA ($1.97) -30.82 %
Price % Change (52-Week) -0.35 %
Shares Float 58,780,000
Total Shares Outstanding 92,360,000
% Owned by Insiders 30.22 %
% Owned by Institutions 42.60 %
Market Cap. 125,609,600
Trading Volume - Today 561,053
Trading Volume - Average 328,700
Trading Volume - Today vs. Average 77.27 %
Earnings Per Share 0.00
PE Ratio 0.00
Record Date 2016-MarA
Sector Healthcare
Industry Biotechnology
Form 3 NORTHWEST BIOTHERAPEUTIC For: Jan 25 Filed by: BLACK COFER
10K WIZARD 3:47 PM ET 3/16/2016
http://archive.fast-edgar.com/20160316/APA2W22CZZ22B9ZZ2HZK2ZZDS5GICB22Z28G
Filed on: March 16, 2016
senti, I am on the same page with you on this post as enrollment was complete when it was changed to "This Study is ongoing but not recruiting participants."
I like the following from your post and sounds like ramp up to commercialization.
I think you are the right call on a deal is movi,g along and trading volume will show when we are getting close to a deal getting announced.
A cancer cure in just one jab? British scientists say they have found the disease's 'Achilles heel' paving the way for 'revolutionary' new treatments
British scientists today claimed to have found cancer's Achilles' heel
In future, patients could be given bespoke therapies that hunt out and destroy every single cancer cell, wherever it is in their body
The first people could be treated in as little as two years, scientists say
Charity: 'It could prove a revolutionary way to treat or even cure disease'
By FIONA MACRAE SCIENCE EDITOR FOR THE DAILY MAIL
PUBLISHED: 14:00 EST, 3 March 2016 | UPDATED: 20:00 EST, 3 March 2016
http://www.dailymail.co.uk/health/article-3475196/Cancer-revolution-scientists-discover-immune-hunt-kill-diseased-cell-body.html
UK House of Commons
Petitions Committee
Funding for research
into brain tumours
First Report of Session 2015–16
http://www.publications.parliament.uk/pa/cm201516/cmselect/cmpetitions/554/554.pdf
NWBO Earnings Due Monday, March 14th....
Great article, thanks for sharing mapman!
European Regulator Ready For Prime Time
Mar. 9, 2016 4:42 PM ET|1 comment | Includes: GSK, MK
Great news for her and her family! I hope she continues to have clear MRI's going forward. Brain cancer patient needs new SOC as it is such a terrible disease, great news so far with for her, 415 days since surgery! I hope she continues to beat this beast.
Thanks for sharing Follower!
Great find, thanks for sharing this on GBM!
Bid and Ask moving up again today? Low volume too!
Yes last paragraph but also like the whole PR but definitely last 3 paragraphs says it all!
With this PR in UK being public knowledge 10/28/2015 and such a positive statement with allocation of $2M British pounds per year being invested to build out European manufacturing for DCVax, why no PR from NWBO unless there is something bigger going requiring participation with each regulatory agency. Just speculating here but this PR in UK provides quite telling information on manufacturing build out including Fraunhofer in Germany, Sawston in UK, and Memphis, etc.
Thanks for the reminder TC!
Thanks Reefrad as it is appreciated by many that you take the time to respond being an expert in this topic as you are a radiologist professional.
Some of these posters sound like my father in law who is not a cardiac surgeon but acts like he knows more about heart related issues than the cardiologist.
Awesome news for your friend! Very encouraging being on DCVax and thanks for sharing! I enclosed your original post to help understand what your friend has gone through fighting this horrible cancer.
Austin you are speculating on the patients not being NWBO. We do not know as they did not provide the company or companies behind this clip. The lung cancer patient could very well be on Direct? You do not know this nor do I.
Doc....totally agree on where a significant investment of funds has gone to manufacturing and automation for commercialization. I also agree on label extensions for other solid tumors once approved is huge opportunity as well. I also agree with Flip on UK commitment of $ for commercial expansion of DCVax manufacturing hub for Europe as noted in Oct 2015.
Thanks mapman!
Curious as to the other short squeeze you see coming? Can you PM me if you do not mind? Thank you.
Thanks Jumpin! Hope we see a deal get done with Shire, Pfizer or another BP
Does anyone know when Pfizer will publish results on Ponezumab or Shire on FA? What is usual timeline from trial complete to results published?
We can agree to disagree Austin. I have no issue with that and you have a right to share your opinion.
I have to disagree if you feel people posting on a message board are more qualified than professionals in their field in this trial to determine which patients have progressed and classify them as pseudo, rapid, etc.
I have been here as long pre Nasdaq and my due diligence was based on the science whi
ch I still believe will prove to be successful in gaining approval with regulators in US, Canada and Europe. JMO.
Senti, this is not directed to you but to others who post contesting the breakdown in the information arm.
It really is surprising to me how some post on this board want to change the breakdown of patients for pseudos, rapids and inderminates data that we have from NWBO's presentations. Are any of these posters educated, trained and qualified experts in this field? have years of experience and assume they know the breakdown of the Information Arm patients better than the experts who have them categorized as they see it?
Am I missing something here?
Great find Evaluate! I had not seen this before. Thanks for sharing!
Great news for your friend on DCVa-L and it is just amazing since diagnosed in 2011 and doing well, QOL is so important and one reason why DCVax-L will be approved.
Keep us updated as you continue to hear on his well being. Thank you for sharing.